Impact of DPP-4 inhibition on acute and chronic endothelial function in humans with type 2 diabetes on background metformin therapy

Vascular Medicine (United Kingdom)

Volumn 22, Issue 3, 2017, Pages 189-196

  Widlansky, Michael E ^a   Puppala, Venkata K ^a   Suboc, Tisha M ^a   Malik, Mobin ^a   Branum, Amberly ^a   Signorelli, Kara ^a   Wang, Jingli ^a   Ying, Rong ^a   Tanner, Michael J ^a   Tyagi, Sudhi ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

DPP 4 inhibition; endothelium; inflammation; nitric oxide; sitagliptin; vascular

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; HEMOGLOBIN A1C; INTERCELLULAR ADHESION MOLECULE 1; METFORMIN; PLACEBO; SITAGLIPTIN; VASCULAR CELL ADHESION MOLECULE 1; BIOLOGICAL MARKER; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DPP4 PROTEIN, HUMAN; ICAM1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BLOOD VESSEL REACTIVITY; BRACHIAL ARTERY; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; ENZYME INHIBITION; FEMALE; HUMAN; INFLAMMATION; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VASCULAR ENDOTHELIUM; VASCULARIZATION; VASODILATATION; BLOOD; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; TIME FACTOR; TREATMENT OUTCOME; WISCONSIN; YOUNG ADULT;

ADULT; AGED; BIOMARKERS; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; MALE; METFORMIN; MIDDLE AGED; SITAGLIPTIN PHOSPHATE; TIME FACTORS; TREATMENT OUTCOME; VASCULAR CELL ADHESION MOLECULE-1; VASODILATION; WISCONSIN; YOUNG ADULT;

EID: 85019239505     PISSN: 1358863X     EISSN: 14770377     Source Type: Journal    
DOI: 10.1177/1358863X16681486     Document Type: Article

References (45)

1. Gokce N, Keaney JF Jr, Vita JA., Endotheliopathies: Clinical manifestations of endothelial dysfunction. In: Loscalzo J, Shafer AI, (eds) Thrombosis and Hemorrhage. Philadelphia, PA: Lippincott Williams and Wilkins, 1998, pp. 901-924.
2. Widlansky ME, Gokce N, Keaney JF Jr, et al. The clinical implications of endothelial dysfunction. J Am Coll Cardiol 2003; 42: 1149-1160.
3. Vita JA, Keaney JF Jr., Endothelial function: A barometer for cardiovascular risk? Circulation 2002; 106: 640-642.
4. Ting HH, Timimi FK, Boles KS, et al. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J Clin Invest 1996; 97: 22-28.
5. Williams SB, Cusco JA, Roddy MA, et al. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 1996; 27: 567-574.
6. McVeigh GE, Brennan GM, Johnston GD, et al. Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1992; 35: 771-776.
7. Steinberg HO, Chaker H, Leaming R, et al. Obesity/insulin resistance is associated with endothelial dysfunction: Implications for the syndrome of insulin resistance. J Clin Invest 1996; 97: 2601-2610.
8. Keaney JF Jr, Massaro JM, Larson MG, et al. Heritability and correlates of intercellular adhesion molecule-1 in the Framingham Offspring Study. J Am Coll Cardiol 2004; 44: 168-173.
9. Meigs JB, Hu FB, Rifai N, et al. Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus. JAMA 2004; 291: 1978-1986.
10. De Jongh RT, Serné EH, IJzerman RG, et al. Impaired microvascular function in obesity: implications for obesity-associated microangiopathy, hypertension, and insulin resistance. Circulation 2004; 109: 2529-2535.
11. Williams SB, Goldfine AB, Timimi FK, et al. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 1998; 97: 1695-1701.
12. Brownlee M., Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-820.
13. Tabit CE, Chung WB, Hamburg NM, et al. Endothelial dysfunction in diabetes mellitus: Molecular mechanisms and clinical implications. Rev Endocr Metab Disord 2010; 11: 61-74.
14. Nystrom T, Gutniak MK, Zhang Q, et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004; 287: E1209-E1215.
15. Ding L, Zhang J., Glucagon-like peptide-1 activates endothelial nitric oxide synthase in human umbilical vein endothelial cells. Acta Pharmacol Sin 2012; 33: 75-81.
16. Matheeussen V, Baerts L, De MG, et al. Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries. Biol Chem 2011; 392: 189-198.
17. Drucker DJ., Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: Preclinical biology and mechanisms of action. Diabetes Care 2007; 30: 1335-1343.
18. Shah Z, Pineda C, Kampfrath T, et al. Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways. Vascul Pharmacol 2011; 55: 2-9.
19. Matsubara J, Sugiyama S, Sugamura K, et al. A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. J Am Coll Cardiol 2012; 59: 265-276.
20. Tang ST, Su H, Zhang Q, et al. Sitagliptin inhibits endothelin-1 expression in the aortic endothelium of rats with streptozotocin-induced diabetes by suppressing the nuclear factor-κB/IκBα system through the activation of AMP-activated protein kinase. Int J Mol Med 2016; 37: 1558-1566.
21. Salheen SM, Panchapakesan U, Pollock CA, et al. The DPP-4 inhibitor linagliptin and the GLP-1 receptor agonist exendin-4 improve endothelium-dependent relaxation of rat mesenteric arteries in the presence of high glucose. Pharmacol Res 2015; 94: 26-33.
22. Brenner C, Krankel N, Kuhlenthal S, et al. Short-term inhibition of DPP-4 enhances endothelial regeneration after acute arterial injury via enhanced recruitment of circulating progenitor cells. Int J Cardiol 2014; 177: 266-275.
23. Liu L, Liu J, Tian XY, et al. Uncoupling protein-2 mediates DPP-4 inhibitor-induced restoration of endothelial function in hypertension through reducing oxidative stress. Antioxid Redox Signal 2014; 21: 1571-1581.
24. Van Poppel PC, Netea MG, Smits P, et al. Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes. Diabetes Care 2011; 34: 2072-2077.
25. Ayaori M, Iwakami N, Uto-Kondo H, et al. Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients. J Am Heart Assoc 2013; 2: e003277.
26. Kizhakekuttu TJ, Wang J, Dharmashankar K, et al. Adverse alterations in mitochondrial function contribute to type 2 diabetes mellitus-related endothelial dysfunction in humans. Arterioscler Thromb Vasc Biol 2012; 32: 2531-2539.
27. Herman GA, Bergman A, Liu F, et al. Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J Clin Pharmacol 2006; 46: 876-886.
28. Widlansky ME, Price DT, Gokce N, et al. Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension. Hypertension 2003; 42: 310-315.
29. Kizhakekuttu TJ, Gutterman DD, Phillips SA, et al. Measuring FMD in the brachial artery: How important is QRS-gating? J Appl Physiol 2010; 109: 959-965.
30. Widlansky ME, Duffy SJ, Hamburg NM, et al. Effects of black tea consumption on plasma catechins, markers of oxidative stress and inflammation in patients with coronary artery disease. Free Radic Biol Med 2004; 38: 499-506.
31. Widlansky ME, Hamburg NM, Anter E, et al. Acute EGCG supplementation reverses endothelial dysfunction in patients with coronary artery disease. J Am Coll Nutr 2007; 26: 95-102.
32. Dharmashankar K, Widlansky ME., Vascular endothelial function and hypertension: Insights and directions. Curr Hypertens Rep 2010; 12: 448-455.
33. Kizhakekuttu TJ, Gutterman DD, Phillips SA, et al. Measuring FMD in the brachial artery: How important is QRS gating? J Appl Physiol 2010; 109: 959-965.
34. De Roos NM, Bots ML, Schouten EG, et al. Within-subject variability of flow-mediated vasodilation of the brachial artery in healthy men and women: Implications for experimental studies. Ultrasound Med Biol 2003; 29: 401-406.
35. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: A report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39: 257-265.
36. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015; 373: 232-242.
37. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369: 1327-1335.
38. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317-1326.
39. Basu A, Charkoudian N, Schrage W, et al. Beneficial effects of GLP-1 on endothelial function in humans: Dampening by glyburide but not by glimepiride. Am J Physiol Endocrinol Metab 2007; 293: E1289-E1295.
40. Ceriello A, Esposito K, Testa R, et al. The possible protective role of glucagon-like peptide 1 on endothelium during the meal and evidence for an 'endothelial resistance' to glucagon-like peptide 1 in diabetes. Diabetes Care 2011; 34: 697-702.
41. Tesauro M, Schinzari F, Adamo A, et al. Effects of GLP-1 on forearm vasodilator function and glucose disposal during hyperinsulinemia in the metabolic syndrome. Diabetes Care 2013; 36: 683-689.
42. Kelly AS, Bergenstal RM, Gonzalez-Campoy JM, et al. Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: A randomized trial. Cardiovasc Diabetol 2012; 11: 64.
43. Irace C, De Luca S, Shehaj E, et al. Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: Results from an observational research. Diab Vasc Dis Res 2013; 10: 72-77.
44. Lovshin J, Cherney D., GLP-1R agonists and endothelial dysfunction: More than just glucose lowering? Diabetes 2015; 64: 2319-2321.
45. Scherrer U, Randin D, Vollenweider P, et al. Nitric oxide release accounts for insulin's vascular effects in humans. J Clin Invest 1994; 94: 2511-2515.